Print PDF

ACC-SFBA Patent Law Committee Meeting Sponsored by Sheppard Mullin LLP

Market Exclusivity – FDA Considerations in Patent Product Protection Strategies
Garden Court Hotel, Palo Alto


Protecting a company’s substantial investment in drug and biologic discovery is key to a product’s commercial success. Market exclusivity has the potential to drive innovation for large and small molecules, and also orphan drugs and other niche drugs with a limited market. In this session, we will explore strategies for maximizing exclusivity from both a patent and FDA regulatory perspective. We also will discuss the opportunities and challenges of attaining market exclusivity from in-house attorneys at both large and small molecule companies.


  • Allison Fulton, Partner, Sheppard Mullin 
  • Lauren Stevens, Consultant, Global Patent Group, LLC 
  • Leslie Robbins, Senior VP Intellectual Property, CytomX Therapeutics
  • Lorna Tanner, Partner, Sheppard Mullin

11:30 a.m. - 12:00 p.m. Registration 
12:00 p.m. - 1:00 p.m. Program
1:00 p.m. - 1:30 p.m. Networking

Credits: 1 Hour
State: CA
Category: General

Garden Court Hotel
520 Cowper Street
Palo Alto, CA

Members: Free 
Non-members: $50

Questions? Please contact Belinda Ashong via email or 415.774.3171

Practice Areas


Jump to Page

By scrolling this page, clicking a link or continuing to browse our website, you consent to our use of cookies as described in our Cookie and Advertising Policy. If you do not wish to accept cookies from our website, or would like to stop cookies being stored on your device in the future, you can find out more and adjust your preferences here.